Abstract:Monoclonal antibodies are of great use in research and clinic. The first monoclonal antibody production method, hybridoma technology, was marked in the paper "Continuous cultures of fused cells secreting antibody of predefined specificity" by Milstein and Kohler in 1975 in Nature. Based on that paper, we took a retrospective and forward look of this technique. In the early research of antibodies and B cells, the low specificity and bad reproductivity of polyclonal antibodies called for new methods to produce highly specific antibodies. Fortunately, the scientists encountered the key prerequisites of the hybridoma method: (1) Mouse multiple myeloma cell lines, which can secrete antibodies and infinitely reproduce in vitro; (2) SRBC (sheep red blood cell) plates that can screen the cells secreteing anti-SRBC antibodies; (3) proper cell fusion methods like Sendai virus and PEG. Based on all these materials and methods, Milstein and Kohler fused spleen cells of immunized mice with mouse myeloma cell line P3-X67Ag8 by inactivated Sendai virus and screened to clone the fused cells that can secrete anti-SRBC antibodies. They also used HAT medium to ensure that only fused cells from spleen cells and myeloma cells can survive. In this way, they obtained the immortal cells that can produce a single type of antibody with a predefined antigen-specificity, or say, hybridoma cells that can produce monoclonal antibodies. This powerful tool of hybridoma was quickly applied and improved. Milstein and Kohler were awarded the Nobel prize and Lasker award in 1984. Despite the great commercial potential of hybridoma in medication and science research, Milstein and Kohler did not patent the method, making it free to use by anyone in the world. The monoclonal antibodies produced by hybridoma were proved highly versatile in the laboratory. Besides great insights provided to us in basic immunology research, they become the indispensable tool to precisely qualify, quantify, and localize macromolecule in all fields of research. Fluorescence imaging, Western blotting, flow cytometry and microarray methods all make use of monoclonal antibodies. Upon chimera, humanized and human monoclonal antibody development, the application and success of monoclonal antibodies on the biopharma market are even greater. Monoclonal antibody medicines to treat cancer and autoimmune diseases are making billions of dollars every year. Notably, among these medicines, anti-PD-1 and anti-CTLA-4 are awarded Nobel prize in 2018 as anti-tumor immune checkpoint inhibitors. Monoclonal antibody medicines for contagious diseases like Ebola also shows advantages over others. For the new outbreak of COVID-19 around the world, monoclonal antibodies are also promising in offering new cures. Presently, the production of monoclonal antibodies is no longer solely dependent on hybridoma technology. Transgenic and recombinant DNA technology are creating new possibilities in this ever-growing field.

Molecular recognition and the future of monoclonal antibodies

Cellular proteins reactive with monoclonal antibodies directed against simian virus 40 T-antigen

Monoclonal Antibodies: Emergence, Present and Outlook

Reactivity of a Novel Monoclonal Antibody ZCH-2B8a on Normal Hematopoietic Cells and Malignant Cell Lines and Its Significance

An immunochemical investigation of SV40 T antigens 1. Production properties and specificity of a rabbit antibody to purified simian virus 40 large-T antigen

Detection of T and B cells in many animal species using cross-reactive anti-peptide antibodies.

Use of monoclonal antibodies as probes of simian virus 40 T antigen ATPase activity.

Reactivity and epitope mapping of single-chain T cell receptors with monoclonal antibodies

Monoclonal antibodies: technologies for early discovery and engineering

The role of therapeutic antibodies in drug discovery

The history of monoclonal antibody development – Progress, remaining challenges and future innovations

Two monoclonal antibodies to precisely the same epitope of type II collagen select non-crossreactive phage clones by phage display: implications for autoimmunity and molecular mimicry

Monoclonal antibody analysis of p53 expression in normal and transformed cells

Therapeutic Monoclonal Antibodies to Complex Membrane Protein Targets: Antigen Generation and Antibody Discovery Strategies

When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions

Epitope promiscuity of human monoclonal autoantibodies to T-cell receptor-combining site determinants

Deciphering CD4+ T cell specificity using novel MHC–TCR chimeric receptors

Monoclonal antibodies — a proven and rapidly expanding therapeutic modality for human diseases

Antibody Surface Profiling Identifies Glycoforms in Multiple Myeloma as Targets for Immunotherapy: From Antibody Derivatives to Mimetic Peptides for Killing Tumor Cells

Molecular biology and immunology for clinicians 23: autoimmunity and the superfamilies of tumor necrosis factor and tumor necrosis factor receptor.

Building better monoclonal antibody-based therapeutics